Oral Corticosteroids for Teprotumumab-Related Hearing Loss: A Case Report
Teprotumumab is a novel insulin-like growth factor-1 receptor inhibitor approved for the treatment of thyroid eye disease, but growing reports of hearing loss require further investigation. To date, an effective protocol for managing hearing loss in this setting has not been determined. Here, we pre...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2023-04-01
|
| Series: | Case Reports in Ophthalmology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/529422 |